TSEN54 Antibody

What is TSEN54 and what is its primary biological function?

TSEN54 (tRNA-splicing endonuclease subunit Sen54) functions as a non-catalytic subunit of the tRNA splicing endonuclease heterotetramer. This complex is responsible for the identification and cleavage of splice sites in precursor tRNAs. Specifically, it cleaves pre-tRNA at the 5' and 3' splice sites to release introns, producing an intron and two tRNA half-molecules bearing 2',3' cyclic phosphate and 5'-OH termini . While there are no conserved sequences at the splice sites, the intron location is invariably positioned at a consistent distance from the constant structural features of the tRNA body . Beyond tRNA processing, TSEN54 is also involved in mRNA processing through association with pre-mRNA 3'-end processing factors, establishing a link between pre-tRNA splicing and pre-mRNA 3'-end formation .

What molecular characteristics should researchers know about TSEN54 protein?

When working with TSEN54 protein, researchers should note:

The discrepancy between calculated and observed molecular weights (59 kDa vs. 54 kDa) should be considered when interpreting Western blot results .

Which species and tissue types show consistent TSEN54 reactivity with available antibodies?

Most commercially available TSEN54 antibodies demonstrate consistent reactivity with human, mouse, and rat samples . Specifically, positive Western blot detection has been confirmed in multiple human cell lines including Jurkat cells, MCF-7 cells, and PC-3 cells . When selecting an antibody for your research, verify the species reactivity from the manufacturer's validation data, as some antibodies may have broader cross-reactivity based on epitope conservation. Several antibodies have undergone extensive validation for specific applications and species combinations, but novel combinations may require additional optimization .

What are the optimal applications for TSEN54 antibody detection and their respective protocols?

TSEN54 antibodies have been validated for several experimental applications:

For Western blotting protocols, manufacturers typically recommend sample-dependent optimization, with initial dilution ranges between 1:5000-1:50000 for highly sensitive antibodies . Always consult product-specific protocols for optimal results, as some antibodies may require specific buffer conditions or blocking reagents to minimize background.

How should samples be prepared for optimal TSEN54 detection in Western blot applications?

For optimal TSEN54 detection in Western blot applications, consider these methodological steps:

• Cell/Tissue Lysis: Use standard RIPA or NP-40 lysis buffers with protease inhibitors to preserve protein integrity.

• Protein Quantification: Standardize protein loading (typically 20-50 μg per lane) using BCA or Bradford assays.

• Gel Selection: Use 10-12% SDS-PAGE gels for optimal resolution of TSEN54 (observed at 54 kDa) .

• Transfer Conditions: Standard semi-dry or wet transfer to PVDF or nitrocellulose membranes is suitable.

• Positive Controls: Include lysates from Jurkat cells, MCF-7 cells, or PC-3 cells, which consistently show TSEN54 expression .

• Antibody Dilution: Start with manufacturer's recommended dilution, but titration may be necessary for optimal signal-to-noise ratio.

• Detection Method: Both chemiluminescence and fluorescence-based detection systems work well with properly optimized antibody concentrations.

Researchers should note that TSEN54 expression levels may vary between tissue types and developmental stages, so appropriate positive controls should be selected based on the research context .

What experimental controls should be included when conducting TSEN54 antibody-based studies?

When designing experiments using TSEN54 antibodies, incorporate these essential controls:

• Positive Controls: Include cell lysates known to express TSEN54, such as Jurkat, MCF-7, or PC-3 cells .

• Negative Controls: Consider using:

  • Primary antibody omission control

  • Isotype control antibody (matching host species and isotype)

  • TSEN54 knockdown/knockout samples when available

• Loading Controls: Include housekeeping proteins (β-actin, GAPDH, α-tubulin) to normalize expression levels.

• Antibody Validation Controls:

  • Peptide competition assay to confirm specificity

  • Multiple antibodies targeting different epitopes for validation

  • Cross-verification with orthogonal techniques (qPCR for mRNA expression)

• Technical Replicates: Perform experiments in triplicate to ensure reproducibility.

These controls help distinguish specific from non-specific signals and validate experimental findings, especially important given the varying expression of TSEN54 across different tissue types and pathological conditions .

How is TSEN54 expression altered in hepatocellular carcinoma and what are the implications for cancer research?

Recent comprehensive analyses have revealed significant alterations in TSEN54 expression in hepatocellular carcinoma (HCC):

• Upregulation in HCC: TSEN54 expression is significantly higher in HCC tissues compared to normal liver tissues, as consistently demonstrated across multiple databases including TIMER, HCCDB, and TCGA .

• Clinical Correlation: TSEN54 expression correlates with several clinicopathological features in HCC patients:

  • Higher expression in advanced tumor grades and stages

  • Association with TP53 mutation status

  • Correlation with race and gender differences

• Prognostic Value: HCC patients with high TSEN54 expression typically have shorter survival expectations, suggesting its potential as a prognostic biomarker .

• Molecular Mechanisms: Functional enrichment analysis revealed TSEN54 involvement in:

  • Cell cycle regulation

  • Metabolic processes

  • Immune cell infiltration

  • Positive correlation with several immune checkpoints and m6A-related regulators

These findings position TSEN54 as a promising candidate for HCC diagnosis, prognosis assessment, and potentially as a therapeutic target. Researchers should consider incorporating TSEN54 expression analysis in comprehensive cancer biomarker panels, particularly for studies involving liver malignancies .

What is the relationship between TSEN54 methylation and its expression in cancer?

The relationship between TSEN54 methylation and expression reveals important epigenetic regulation mechanisms in cancer:

• Hypomethylation in HCC: TSEN54 promoter methylation levels are significantly lower in HCC tissues compared to normal liver samples .

• Inverse Correlation: A negative correlation exists between TSEN54 methylation and its mRNA expression, suggesting that hypomethylation contributes to increased TSEN54 expression in HCC .

• Clinical Associations: TSEN54 promoter methylation levels are associated with:

  • Clinical stage

  • Histological grade

  • Lymph node metastasis

  • TP53 mutation status

  • Gender differences (lower methylation in female patients)

• Methodological Considerations: Researchers investigating this relationship should:

  • Employ both expression and methylation analyses in parallel

  • Consider using platforms that allow integrated multi-omics approaches

  • Validate findings using both bioinformatic analyses and experimental verification

These observations suggest that epigenetic mechanisms play a crucial role in regulating TSEN54 expression in cancer, highlighting the importance of integrating methylation analysis with expression studies when investigating TSEN54 as a cancer biomarker .

How does TSEN54 expression correlate with immune cell infiltration and potential immunotherapy targets?

Research has uncovered significant relationships between TSEN54 expression and tumor immune microenvironment:

• Immune Cell Infiltration: TSEN54 expression shows positive correlations with infiltration levels of multiple immune cell types in HCC, suggesting its potential role in shaping the tumor immune microenvironment .

• Chemokine Expression: Positive relationships have been observed between TSEN54 expression and several chemokines, which may influence immune cell recruitment and function in the tumor microenvironment .

• Immune Checkpoint Correlation: TSEN54 expression correlates with the expression levels of several immune checkpoint molecules, suggesting potential implications for immunotherapy response prediction .

• m6A Modification Connection: TSEN54 is linked to several m6A-related regulators, indicating potential roles in RNA modification processes that could influence immune responses .

For researchers investigating TSEN54 in the context of cancer immunology, these findings suggest the value of:

• Integrating TSEN54 expression analysis with immune profiling

• Exploring TSEN54 as a potential predictive biomarker for immunotherapy response

• Investigating the mechanistic connections between TSEN54, RNA processing, and immune regulation

These correlations provide a foundation for further mechanistic studies to understand how TSEN54's RNA processing functions might influence immune regulation in cancer .

Why might there be discrepancies between the calculated (59 kDa) and observed (54 kDa) molecular weights for TSEN54 in Western blot analysis?

Several factors may explain the discrepancy between calculated (59 kDa) and observed (54 kDa) molecular weights for TSEN54:

• Post-translational Modifications: The protein may undergo processing that alters its apparent molecular weight, such as:

  • Proteolytic cleavage

  • Differential phosphorylation states

  • Other modifications affecting protein mobility

• Protein Structure: The folded conformation of TSEN54 may cause it to migrate faster than predicted based solely on amino acid sequence.

• Technical Factors:

  • Gel percentage and running conditions can affect protein migration

  • Buffer systems and SDS concentration may influence apparent molecular weight

  • Reference protein ladder calibration variations

• Isoform Detection: TSEN54 exists in multiple isoforms through alternative splicing , and antibodies may preferentially detect specific isoforms.

• Verification Approaches:

  • Use multiple antibodies targeting different epitopes

  • Include recombinant TSEN54 protein as a positive control

  • Perform knockdown/knockout validation to confirm specificity

Researchers should report both calculated and observed molecular weights in publications and consider these factors when interpreting Western blot results .

What approaches are recommended for quantifying TSEN54 expression in research samples?

For accurate quantification of TSEN54 expression, researchers should consider these methodological approaches:

• Protein Expression Quantification:

  • Western Blot: Use densitometry with normalization to loading controls (β-actin, GAPDH)

  • ELISA: For more precise quantification in suitable sample types

  • Immunohistochemistry Scoring: Consider H-score or other semi-quantitative methods for tissue sections

• mRNA Expression Quantification:

  • RT-qPCR: With validated TSEN54-specific primers and appropriate reference genes

  • RNA-Seq: For transcriptome-wide analysis and isoform detection

• Standardization Practices:

  • Include standard curves with recombinant proteins for absolute quantification

  • Use multiple technical and biological replicates

  • Employ multiple methodologies for cross-validation

• Data Normalization Strategies:

  • For tissue samples: normalize to tissue area, cell number, or total protein

  • For cell lines: standardize to cell number or total protein

  • Consider using multiple housekeeping genes/proteins for more robust normalization

• Statistical Analysis:

  • Employ appropriate statistical tests based on data distribution

  • Consider using fold-change relative to controls rather than absolute values

  • Report confidence intervals alongside means/medians

These approaches help ensure reliable and reproducible quantification of TSEN54 expression across different experimental contexts and sample types .

How is TSEN54 implicated in pontocerebellar hypoplasia and what methodologies are used to study these mutations?

TSEN54 plays a critical role in pontocerebellar hypoplasia (PCH), a group of neurodevelopmental disorders:

• Disease Association:

  • Mutations in TSEN54 are associated with pontocerebellar hypoplasia types 2A and 4

  • These conditions are characterized by significant structural abnormalities in the cerebellum, inferior olive, and ventral pons

• Mutation Analysis Methodologies:

  • Targeted Sequencing: Focusing on known TSEN54 mutations

  • Whole Exome/Genome Sequencing: For comprehensive genetic analysis

  • Functional Validation: Using cellular models to assess the impact of mutations on tRNA processing

• Experimental Approaches:

  • Patient-Derived Cells: To study the functional consequences of mutations

  • Animal Models: To understand developmental impacts of TSEN54 dysfunction

  • In Vitro tRNA Processing Assays: To directly measure enzymatic activity alterations

• Molecular Mechanisms:

  • Disruption of tRNA splicing affecting protein synthesis

  • Potential impacts on pre-mRNA processing

  • Secondary effects on neuronal development and survival

For researchers studying TSEN54 in the context of neurological disorders, integration of genetic, biochemical, and cellular approaches provides the most comprehensive understanding of pathogenic mechanisms .

What is the prognostic significance of TSEN54 expression in hepatocellular carcinoma and how should researchers approach biomarker validation?

TSEN54 shows significant promise as a prognostic biomarker in hepatocellular carcinoma (HCC):

• Prognostic Value:

  • HCC patients with high TSEN54 expression typically have shorter survival expectations

  • Expression correlates with multiple clinicopathological features including tumor grade, stage, and TP53 mutation status

• Biomarker Validation Approach:

  • Discovery Phase: Initial identification through multi-omics approaches

  • Validation Phase: Independent cohort testing with standardized methodologies

  • Clinical Implementation: Prospective studies to confirm utility

• Methodological Considerations:

  • Use multiple detection methods (IHC, qPCR, protein assays)

  • Standardize scoring/quantification systems

  • Establish clinically relevant cutoff values

  • Integrate with existing biomarker panels

• Mechanistic Investigations:

  • Explore TSEN54's role in cell cycle regulation

  • Investigate connections to immune infiltration

  • Examine relationships with m6A modification

  • Study impacts on RNA processing in cancer cells

• Translational Applications:

  • Potential for inclusion in prognostic models

  • Possible therapeutic target development

  • Patient stratification for clinical trials

Researchers should adopt a systematic, multi-phase approach to validating TSEN54 as a biomarker, incorporating both expression analysis and functional studies to establish its clinical utility .